scholarly journals Correction: PAMAM/5-fluorouracil drug conjugate for targeting E6 and E7 oncoproteins in cervical cancer: a combined experimental/in silico approach

RSC Advances ◽  
2017 ◽  
Vol 7 (19) ◽  
pp. 11281-11281 ◽  
Author(s):  
Arunkumar Rengaraj ◽  
Balaji Subbiah ◽  
Yuvaraj Haldorai ◽  
Dhanusha Yesudhas ◽  
Hyung Joong Yun ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
In Silico ◽  
Drug Conjugate ◽  
E6 And E7 Oncoproteins ◽  
E6 And E7

Correction for ‘PAMAM/5-fluorouracil drug conjugate for targeting E6 and E7 oncoproteins in cervical cancer: a combined experimental/in silico approach’ by Arunkumar Rengaraj et al., RSC Adv., 2017, 7, 5046–5054.

scholarly journals PAMAM/5-fluorouracil drug conjugate for targeting E6 and E7 oncoproteins in cervical cancer: a combined experimental/in silico approach

RSC Advances ◽  
2017 ◽  
Vol 7 (9) ◽  
pp. 5046-5054 ◽  
Author(s):  
Arunkumar Rengaraj ◽  
Balaji Subbiah ◽  
Yuvaraj Haldorai ◽  
Dhanusha Yesudhas ◽  
Hyung Joong Yun ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
In Silico ◽  
Conjugate System ◽  
Cervical Cancers ◽  
Drug Conjugate ◽  
E6 And E7 Oncoproteins ◽  
E6 And E7

In the present study, poly(amidoamine)/5-fluorouracil (PAMAM/5-FU) was used as a conjugate system for delivering drugs to target E6 and E7 oncoproteins, which are predominant in cervical cancers.

E6 and E7 oncoproteins: Potential targets of cervical cancer

2020 ◽  
Vol 27 ◽  
Author(s):  
Ramarao Malla ◽  
Mohammad Amjad Kamal
Keyword(s):  
Cervical Cancer ◽  
Drug Resistance ◽  
Host Cell ◽  
Molecular Mechanisms ◽  
Immune Therapy ◽  
Cervical Lesions ◽  
Diagnostic Strategies ◽  
E6 And E7 Oncoproteins ◽  
E6 And E7

: Cervical cancer (CC) is the fourth leading cancer in women in the age group 15-44 globally. Experimental as well as epidemiological studies identified that type16 and 18 HPV cause 70% of precancerous cervical lesions as well as cervical cancer worldwide by bringing about genetic as well as epigenetic changes in the host genome. The insertion of the HPV genome triggers various defense mechanisms including the silencing of tumor suppressor genes as well as activation of oncogenes associated with cancer metastatic pathway. E6 and E7 are small oncoproteins consisting of 150 and 100 amino acids respectively. These oncoproteins affect the regulation of the host cell cycle by interfering with p53 and pRb. Further these oncoproteins adversely affect the normal functions of the host cell by binding to their signaling proteins. Recent studies demonstrated that E6 and E7 oncoproteins are potential targets for CC. Therefore, this review discusses the role of E6 and E7 oncoproteins in metastasis and drug resistance as well as their regulation, early oncogene mediated signaling pathways. This review also uncovers the recent updates on molecular mechanisms of E6 and E7 mediated phytotherapy, gene therapy, immune therapy, and vaccine strategies as well as diagnosis through precision testing. Therefore, understanding the potential role of E6/E7 in metastasis and drug resistance along with targeted treatment, vaccine, and precision diagnostic strategies could be useful for the prevention and treatment of cervical cancer.

Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients

1994 ◽  
Vol 137 (3-4) ◽  
pp. 341-353 ◽  
Author(s):  
I. Nindl ◽  
L. Benitez-Bribiesca ◽  
J. Berumen ◽  
N. Farmanara ◽  
S. Fisher ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Patients ◽  
Conformational Epitopes ◽  
E6 And E7 Oncoproteins ◽  
E6 And E7

scholarly journals Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins

2019 ◽  
Vol 24 (10) ◽  
pp. 2044-2057 ◽  
Author(s):  
Ana M. Almeida ◽  
João A. Queiroz ◽  
Fani Sousa ◽  
Ângela Sousa
Keyword(s):  
Cervical Cancer ◽  
Hpv Infection ◽  
E6 And E7 Oncoproteins ◽  
E6 And E7 ◽  
Therapeutic Research

scholarly journals In Silico Approaches: A Way to Unveil Novel Therapeutic Drugs for Cervical Cancer Management

2021 ◽  
Vol 14 (8) ◽  
pp. 741
Author(s):  
Diana Gomes ◽  
Samuel Silvestre ◽  
Ana Paula Duarte ◽  
Aldo Venuti ◽  
Christiane P. Soares ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Small Molecules ◽  
In Silico ◽  
Access To Health Services ◽  
Cancer Management ◽  
Hpv E6 ◽  
Therapeutic Drugs ◽  
E6 Oncoprotein ◽  
Access To Health ◽  
E6 And E7

Cervical cancer (CC) is the fourth most common pathology in women worldwide and presents a high impact in developing countries due to limited financial resources as well as difficulties in monitoring and access to health services. Human papillomavirus (HPV) is the leading cause of CC, and despite the approval of prophylactic vaccines, there is no effective treatment for patients with pre-existing infections or HPV-induced carcinomas. High-risk (HR) HPV E6 and E7 oncoproteins are considered biomarkers in CC progression. Since the E6 structure was resolved, it has been one of the most studied targets to develop novel and specific therapeutics to treat/manage CC. Therefore, several small molecules (plant-derived or synthetic compounds) have been reported as blockers/inhibitors of E6 oncoprotein action, and computational-aided methods have been of high relevance in their discovery and development. In silico approaches have become a powerful tool for reducing the time and cost of the drug development process. Thus, this review will depict small molecules that are already being explored as HR HPV E6 protein blockers and in silico approaches to the design of novel therapeutics for managing CC. Besides, future perspectives in CC therapy will be briefly discussed.

scholarly journals Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer

2019 ◽  
Vol 12 (10) ◽  
pp. 1289-1295 ◽  
Author(s):  
Zewei Jiang ◽  
Joseph Albanese ◽  
Joshua Kesterson ◽  
Joshua Warrick ◽  
Rouzan Karabakhtsian ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Monoclonal Antibodies ◽  
Human Papillomavirus ◽  
Tumor Growth ◽  
Inhibit Tumor Growth ◽  
E6 And E7 Oncoproteins ◽  
E6 And E7

scholarly journals The Efficacy of Therapeutic DNA Vaccines Expressing the Human Papillomavirus E6 and E7 Oncoproteins for Treatment of Cervical Cancer: Systematic Review

Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 53
Author(s):  
Ayazhan Akhatova ◽  
Chee Kai Chan ◽  
Azliyati Azizan ◽  
Gulzhanat Aimagambetova
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Public Health Problem ◽  
Clinical Implementation ◽  
Therapeutic Vaccines ◽  
Term Survival ◽  
Hpv E6 ◽  
E6 And E7 Oncoproteins ◽  
E6 And E7 ◽  
Lesion Regression

Cervical cancer is recognized as a serious public health problem since it remains one of the most common cancers with a high mortality rate among women despite existing preventative, screening, and treatment approaches. Since Human Papillomavirus (HPV) was recognized as the causative agent, the preventative HPV vaccines have made great progress over the last few years. However, people already infected with the virus require an effective treatment that would ensure long-term survival and a cure. Currently, clinical trials investigating HPV therapeutic vaccines show a promising vaccine-induced T-cell mediated immune response, resulting in cervical lesion regression and viral eradication. Among existing vaccine types (live vector, protein-based, nucleic acid-based, etc.), deoxyribonucleic acid (DNA) therapeutic vaccines are the focus of the study, since they are safe, cost-efficient, thermostable, easily produced in high purity and distributed. The aim of this study is to assess and compare existing DNA therapeutic vaccines in phase I and II trials, expressing HPV E6 and E7 oncoproteins for the prospective treatment of cervical cancer based on clinical efficacy, immunogenicity, viral clearance, and side effects. Five different DNA therapeutic vaccines (GX-188E, VGX-3100, pNGVL4a-CRT/E7(detox), pNGVL4a-Sig/E7(detox)/HSP70, MEDI0457) were well-tolerated and clinically effective. Clinical implementation of DNA therapeutic vaccines into treatment regimen as a sole approach or in combination with conservative treatment holds great potential for effective cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document